AcelRx Pharmaceuticals Inc. (ACRX)

2.20
NASDAQ : Health Technology
Prev Close 2.25
Day Low/High 2.16 / 2.27
52 Wk Low/High 1.99 / 5.05
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 79.44M
Market Cap 178.73M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Stocks Under $10 Weekly Summary

For the second week in a row, we initiated a new position, this time in a security tech name.

Stocks Under $10 Weekly Summary

We initiated a new position for the portfolio during the shortened holiday trading week.

Stocks Under $10 Weekly Summary

We exited three biotech/pharma positions and added to two other holdings during a busy week for the portfolio.

Stocks Under $10 Weekly Summary

We exited two positions today following a tough week for small-cap stocks.

Cutting Inovio Pharma's Rating

We are looking to exit this name, maximizing exit value.

Adding to a Pharma Position, and an Update on Portfolio Earnings

Earnings analysis on four stocks -- and we are increasing our ACRX position on this weakness.

Stocks Under $10 Weekly Summary

Last week, we increased our holdings in one position and added 2 Bullpen names.

Stocks Under $10 Weekly Summary

We used price declines to scale into several holdings as small-caps underperformed the overall market.

What Enzo Biochem's Good News Means for Our Position

Keep a close eye on this one, and establish a stop-loss order at or around $9.50.

Stocks Under $10 Weekly Summary

This week brings earnings from 5 portfolio holdings as the market continues to shrug off potential negatives.

Adding to a Health Care Name

We have to purchase some AcelRx Pharmaceuticals to take advantage of these prices.

Staying on Top of Hudson Technologies

Our plan of action on HDSN and our new price target.

Stocks Under $10 Weekly Summary

We took some profits and added a Bullpen name, among other moves, during a rough week for a few portfolio names.

How We're Playing AcelRx, Antares, AXI and Hudson Tech

Checking out some tough calls.

Adding to AcelRx on Weakness

I prefer to fight back on this one.

Taking Some Profits in Healthcare Name; Adding to Another Position

We'll sell some AcelRx Pharmaceuticals and buy more Hudson Technologies.

Stocks Under $10 Weekly Summary

We added to one name during a stellar week for the majority of the portfolio.

Stocks Under $10 Weekly Summary

We took a healthy profit trimming one name and added to three other positions last week.

Insider Bets Paying Off At ACRX As New 52-Week High Reached

Insider Bets Paying Off At ACRX As New 52-Week High Reached

In trading on Monday, shares of AcelRx Pharmaceuticals Inc touched a new 52-week high of $5.50/share. That's a 182.05% rise, or $3.55 per share from the 52-week low of $1.95 set back on 06/12/2017.

We're Selling at a Fat Profit Part of a Drug Position

We'll take the money and run by selling one-third of our stake in AcelRx Pharmaceuticals.

Stocks Under $10 Weekly Summary

We added a digital security name to the Bullpen during a mixed week for the portfolio.

First Week of ACRX November 17th Options Trading

First Week of ACRX November 17th Options Trading

Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACRX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Stocks Under $10 Weekly Summary

We initiated 2 new positions and jettisoned another over the last week.

Stocks Under $10 Weekly Summary

We remain cautious during this historically volatile month for the market.

Stocks Under $10 Weekly Summary

We scaled into one position during a week dominated by Hurricane Harvey and its aftermath.

Stocks Under $10 Weekly Summary

We initiated 2 small positions last week as the market moved higher.

Stocks Under $10 Weekly Summary

We used last week's weakness to scale into several positions.

Stocks Under $10 Weekly Summary

North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.

Stocks Under $10 Weekly Summary

It was a rough week for the portfolio.

Stick With AcelRx Pharmaceuticals Despite Selloff

Unless there is a dilution event around the corner, the selloff is overdone.

TheStreet Quant Rating: D- (Sell)